MX364930B - Proceso de producción a gran escala de dimesilato de 1-[(2-bromofenil]sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)met il]-1h-indol monohidratado. - Google Patents
Proceso de producción a gran escala de dimesilato de 1-[(2-bromofenil]sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)met il]-1h-indol monohidratado.Info
- Publication number
- MX364930B MX364930B MX2016006629A MX2016006629A MX364930B MX 364930 B MX364930 B MX 364930B MX 2016006629 A MX2016006629 A MX 2016006629A MX 2016006629 A MX2016006629 A MX 2016006629A MX 364930 B MX364930 B MX 364930B
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- bromophenyl
- piperazinyl
- sulfonyl
- methoxy
- Prior art date
Links
- XKDCUJBWVGDNSH-UHFFFAOYSA-N 1-(2-bromophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole;methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O.CS(O)(=O)=O.C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C(=CC=CC=2)Br)C=C1CN1CCN(C)CC1 XKDCUJBWVGDNSH-UHFFFAOYSA-N 0.000 title abstract 2
- 238000011031 large-scale manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
- 238000002636 symptomatic treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Un proceso adecuado para la producción a gran escala de dimesilato de 1-[(2-bromofenil)sulfonil]-5-metoxi-3-[(4-metil-1-pi perazinil)metil]-1H-indol monohidratado, que es un antagonista selectivo del receptor 5-HT6 de uso previsto en el tratamiento sintomático de la enfermedad de Alzheimer y de otros trastornos de la memoria y de la cognición como, por ejemplo, el trastorno por déficit de atención con hiperactividad, la enfermedad de Parkinson y la esquizofrenia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN5537CH2013 IN2013CH05537A (es) | 2013-12-02 | 2014-02-20 | |
| PCT/IN2014/000109 WO2015083179A1 (en) | 2013-12-02 | 2014-02-20 | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006629A MX2016006629A (es) | 2016-08-08 |
| MX364930B true MX364930B (es) | 2019-05-14 |
Family
ID=54199404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006629A MX364930B (es) | 2013-12-02 | 2014-02-20 | Proceso de producción a gran escala de dimesilato de 1-[(2-bromofenil]sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)met il]-1h-indol monohidratado. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9540321B2 (es) |
| EP (1) | EP3077375B1 (es) |
| JP (1) | JP6151453B2 (es) |
| KR (1) | KR101808792B1 (es) |
| CN (1) | CN105814020B (es) |
| AP (1) | AP2016009224A0 (es) |
| AU (1) | AU2014358682B2 (es) |
| BR (1) | BR112016010788B1 (es) |
| CA (1) | CA2929309C (es) |
| CY (1) | CY1119298T1 (es) |
| DK (1) | DK3077375T3 (es) |
| EA (1) | EA028038B1 (es) |
| ES (1) | ES2638856T3 (es) |
| HK (1) | HK1226396B (es) |
| HR (1) | HRP20171245T1 (es) |
| HU (1) | HUE036008T2 (es) |
| IL (1) | IL245619B (es) |
| IN (1) | IN2013CH05537A (es) |
| LT (1) | LT3077375T (es) |
| ME (1) | ME02843B (es) |
| MX (1) | MX364930B (es) |
| NZ (1) | NZ719671A (es) |
| PL (1) | PL3077375T3 (es) |
| PT (1) | PT3077375T (es) |
| RS (1) | RS56323B1 (es) |
| SI (1) | SI3077375T1 (es) |
| WO (1) | WO2015083179A1 (es) |
| ZA (1) | ZA201602954B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050819T2 (hu) * | 2016-05-18 | 2021-01-28 | Suven Life Sciences Ltd | Tiszta 5-HT6 receptor antagonisták kombinációja acetilkolinészteráz inhibitorokkal |
| SG11201809725TA (en) | 2016-05-18 | 2018-12-28 | Suven Life Sciences Ltd | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
| JP6629464B2 (ja) | 2016-05-18 | 2020-01-15 | スヴェン・ライフ・サイエンシズ・リミテッド | 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ |
| US20210346374A1 (en) * | 2016-10-03 | 2021-11-11 | Suven Life Sciences Limited | Pharmaceutical compositions of 5-ht6 receptor antagonist |
| MX2019003815A (es) | 2016-10-03 | 2019-08-12 | Suven Life Sciences Ltd | Composiciones farmaceuticas de antagonista del 5-ht6. |
| KR102508303B1 (ko) * | 2017-07-03 | 2023-03-09 | 수벤 라이프 사이언시스 리미티드 | 순수한 5-ht6 수용체 길항제의 신규 용도 |
| MX2022006535A (es) | 2019-12-02 | 2022-09-09 | Suven Life Sciences Ltd | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
| CN114761008B (zh) | 2019-12-02 | 2024-07-19 | 苏文生命科学有限公司 | 用于在患有痴呆的患者中治疗行为和心理症状的方法 |
| CN111233737B (zh) * | 2020-03-16 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
| CN111362859B (zh) * | 2020-03-16 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
| CN111362858B (zh) * | 2020-03-16 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2749846B1 (fr) * | 1996-06-17 | 1998-09-11 | Pf Medicament | Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique |
| SI1581492T1 (sl) | 2002-11-28 | 2008-12-31 | Suven Life Sciences Ltd | N-arilsulfonil-3-substituirani indoli, ki imajo afiniteto za serotoninski receptor, postopek za njihovo pripravo in farmacevtski sestavek, ki jih vsebuje |
| DK1581538T3 (da) * | 2002-12-18 | 2007-06-25 | Suven Life Sciences Ltd | Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet |
| AU2007257882B2 (en) * | 2006-06-12 | 2011-09-08 | Secura Bio Inc. | Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
-
2014
- 2014-02-20 BR BR112016010788-8A patent/BR112016010788B1/pt active IP Right Grant
- 2014-02-20 EA EA201691161A patent/EA028038B1/ru unknown
- 2014-02-20 EP EP14725245.6A patent/EP3077375B1/en active Active
- 2014-02-20 ES ES14725245.6T patent/ES2638856T3/es active Active
- 2014-02-20 ME MEP-2017-193A patent/ME02843B/me unknown
- 2014-02-20 SI SI201430348T patent/SI3077375T1/sl unknown
- 2014-02-20 PL PL14725245T patent/PL3077375T3/pl unknown
- 2014-02-20 CN CN201480065601.9A patent/CN105814020B/zh active Active
- 2014-02-20 CA CA2929309A patent/CA2929309C/en active Active
- 2014-02-20 IN IN5537CH2013 patent/IN2013CH05537A/en unknown
- 2014-02-20 KR KR1020167013965A patent/KR101808792B1/ko active IP Right Grant
- 2014-02-20 HU HUE14725245A patent/HUE036008T2/hu unknown
- 2014-02-20 DK DK14725245.6T patent/DK3077375T3/en active
- 2014-02-20 WO PCT/IN2014/000109 patent/WO2015083179A1/en active Application Filing
- 2014-02-20 LT LTEP14725245.6T patent/LT3077375T/lt unknown
- 2014-02-20 PT PT147252456T patent/PT3077375T/pt unknown
- 2014-02-20 US US15/100,489 patent/US9540321B2/en active Active
- 2014-02-20 AP AP2016009224A patent/AP2016009224A0/en unknown
- 2014-02-20 MX MX2016006629A patent/MX364930B/es active IP Right Grant
- 2014-02-20 AU AU2014358682A patent/AU2014358682B2/en active Active
- 2014-02-20 JP JP2016535680A patent/JP6151453B2/ja active Active
- 2014-02-20 RS RS20170853A patent/RS56323B1/sr unknown
- 2014-02-20 NZ NZ719671A patent/NZ719671A/en unknown
-
2016
- 2016-05-03 ZA ZA2016/02954A patent/ZA201602954B/en unknown
- 2016-05-11 IL IL245619A patent/IL245619B/en active IP Right Grant
- 2016-12-23 HK HK16114655A patent/HK1226396B/zh unknown
-
2017
- 2017-08-16 HR HRP20171245TT patent/HRP20171245T1/hr unknown
- 2017-08-28 CY CY20171100904T patent/CY1119298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX364930B (es) | Proceso de producción a gran escala de dimesilato de 1-[(2-bromofenil]sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)met il]-1h-indol monohidratado. | |
| UY34144A (es) | ?proceso para la producción de carbonato de calcio precipitado, carbonato de calcio precipitado y sus usos | |
| GB201602297D0 (en) | Process for the synthesis of stable amorphous ibrutinib | |
| IL252200B (en) | A process for the purification of receptor tyrosine kinase inhibitor axl "r 428" | |
| FR3004936B1 (fr) | Procede d'obtention d'un melange d'oligosaccharides neutres extraits de graines de lin. | |
| GB2517000B (en) | Process for the synthesis of oxymorphone alkaloid and oxymorphone salts | |
| FR3004727B1 (fr) | Procede de production d'hydrocarbures | |
| FR3014451B1 (fr) | Procede de production de gaz de synthese par coelectrolyse | |
| CL2016001505A1 (es) | Proceso para la producción de gas de síntesis de amoníaco. | |
| ZA201603839B (en) | Process for the production of synthesis gas | |
| MX366033B (es) | Proceso para produccion a gran escala de oxalato de 1-isopropil-3-{5-[1-(3-metoxipropil) piperidin-4-il]-[1,3,4]oxadia zol-2-il}-1h-indazol. | |
| FR3000737B1 (fr) | Procede de production d'hydrogene. | |
| FR3021316B1 (fr) | Procede d'obtention du borazane | |
| IN2013CH01199A (es) | ||
| HUE054248T2 (hu) | Eljárás kondenzált imidazo-származékok elõállítására | |
| NZ728907A (en) | Active metabolite of 1-[(2-bromophenyl) sulfonyl]-5-methoxy-3- [(4-methyl-1-piperazinyl) methyl]-1h-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite | |
| TH1601003167A (th) | กระบวนการสำหรับการผลิตขนาดใหญ่ของ 1-[(2-โบรโมเฟนิล)ซัลโฟนิล]-5-เมทอกซี-3-[(4-เมทิล-1-พิเพอราซินิล)เมทิล]-1h-อินโดลไดเมซิเลตโมโนไฮเดรต | |
| FR3021317B1 (fr) | Procede d'obtention du borazane | |
| TH166885B (th) | กระบวนการสำหรับการผลิตขนาดใหญ่ของ 1-[(2-โบรโมเฟนิล)ซัลโฟนิล]-5-เมทอกซี-3-[(4-เมทิล-1-พิเพอราซินิล)เมทิล]-1h-อินโดลไดเมซิเลตโมโนไฮเดรต | |
| MA40771B1 (fr) | Forme cristalline de 1-(1-méthyl-1h-pyrazol -4-yl)-n- ((1r,5s,7s) -9-méthyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide | |
| LV14663A (lv) | Pirolo[1,2-a]hinazolīna atvasinājumu sintēze no N-antranilskābes hidrazīdiem un alfa-ketoskābēm | |
| FR3026104B1 (fr) | Procede d'obtention de la l-hercynine pure | |
| EP2970065A4 (en) | METHOD FOR SELECTIVELY PREPARING PROPANOLS BY GLYCEROL HYDROGENATION | |
| TH114500B (th) | กระบวนการสำหรับการผลิตของคลอรีน ไดออกไซด์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |